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In recent years, further concerns have been raised about the 
cardiovascular (CV) safety of non-steroidal anti-inflamma-
tory drugs (NSAIDs) since the first signal was raised about 
rofecoxib [1]. A wide range of observational studies have 
demonstrated the increased risk of cardiac events in NSAIDs 
users. However, in both the prescription and non-prescrip-
tion setting, NSAIDs remain among the most commonly 
used drugs and the uncertainty around their CV safety has 
prompted calls for new and more reliable evidence.
In the current issue of Drug Safety, Duong et al. [2] 
report hospital admissions for acute coronary syndrome 
(ACS), in a French claims database sample, that occurred 
within 3 months after the dispensing of ibuprofen or par-
acetamol. A cohort of 168,400 people prescribed 315,269 
ibuprofen treatment episodes (TEs) were compared, using 
propensity score matching, with a cohort of 395,952 patients 
with 630,457 prescriptions for paracetamol TEs. Across 
the 3-month follow-up period, the rate of CV events was 
similar in each cohort. However, in the first 15 days of treat-
ment there were 2.4/10,000 events in ibuprofen users versus 
1.3/10,000 in paracetamol users, giving a hazard ratio of 1.7 
[95% confidence interval (CI) 1.1–2.6]. This difference was 
driven by the subgroup of low-dose aspirin users (5% of 
the total study population), probably because aspirin is pre-
scribed to high CV risk patients or patients with established 
CV disease. This is either due to direct toxicity from ibupro-
fen or to an interaction between ibuprofen and aspirin that 
results in reduced antiplatelet activity of aspirin in high-risk 
subjects [3]. However, in the following 15 days, the rate of 
events switched to being higher in paracetamol users, possi-
bly because of a depletion of susceptible patients in the first 
2 weeks of ibuprofen use. Of course, such subgroup analysis 
results could simply be due to random variation, but these 
results do suggest that ibuprofen would be best avoided in 
users of low-dose aspirin. This overall finding that ibuprofen 
and paracetamol are similar with regards to CV safety is, 
however, somewhat reassuring for ibuprofen users.
These observational studies are likely to have good 
external validity as subjects are likely to be representative 
of usual healthcare practice. However, observational data 
suffer from channeling and other biases [4] such that high-
risk patients are given the perceived safer CV drug (par-
acetamol) whereas low-risk patients are given the perceived 
riskier NSAID (ibuprofen). Indeed, age is a dominant CV 
risk factor and the subjects in the study by Doung et al. [2] 
taking paracetamol were 10 years older than ibuprofen users.
Recently, two large randomized studies considering CV 
risk with NSAIDs have been reported. These studies have 
better internal validity but are less externally valid as sub-
jects who participate in trials are more likely to be interested 
in their health and thus have lower CV risk overall.
The first study, the PRECISION (Prospective Rand-
omized Evaluation of Celecoxib Integrated Safety vs. Ibu-
profen or Naproxen) trial, was a large randomized controlled 
trial (n = 24,081) of CV safety of celecoxib versus ibupro-
fen or naproxen in patients with arthritis and at moderate 
CV risk. PRECISION formally showed that the selective 
NSAID (celecoxib) had similar CV risks (was non-inferior) 
to the non-selective NSAIDs (ibuprofen and naproxen). 
However, subgroup analysis of the adjudicated outcomes 
showed that the ibuprofen cohort (ibuprofen mean dose of 
2045 ± 246 mg/day) was associated with the worst outcomes 
for many of the CV endpoints and with a significantly higher 
risk of gastrointestinal and renal events [5].
SCOT (Standard care vs. Celecoxib Outcome Trial) was 
a pragmatic randomized trial of prescribed NSAIDs and CV 
safety that investigated the impact of switching half of the 
subjects prescribed NSAIDs in usual care to celecoxib. In 
this study, 7297 patients with osteoarthritis or rheumatoid 
arthritis, free from previous CV events, were randomized 
and followed up for an average of 3.2 years. In SCOT, the 
prescribed ibuprofen dose was lower than in PRECISION 
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(675.9 ± 345.9 vs. 2045 ± 246 mg/day), and there was a very 
low CV event rate both in the selective and non-selective 
NSAIDs arms, suggesting that NSAIDs and celecoxib had 
acceptable CV safety in subjects free from established CV 
disease [6].
A recent Bayesian meta-analysis by Bally et al. [7] on 
the risk of acute myocardial infarction (AMI) with NSAIDs 
in real-world (observational) use showed an increased risk 
of AMI associated with all NSAIDs, selective and non-
selective, with the greatest risk observed with higher doses 
and during the first month of treatment. In particular, this 
meta-analysis showed that use of ibuprofen for 8–30 days 
at doses > 1200 mg was particularly harmful (adjusted odds 
ratio 1.75). These findings suggest that NSAID users have 
a risk of cardiac events that depends primarily on drug 
dose and patient CV risk profile, a finding supported by the 
Doung et al. [2] study.
The Doung et al. [2] study appropriately matched the ibu-
profen cohort with a paracetamol cohort to avoid protopathic 
and indication bias. However, paracetamol was chosen on 
the assumption of its low CV risk profile—an assumption 
that has been questioned. Recently, Sudano et al. [8] dem-
onstrated that paracetamol is associated with a significant 
increase in ambulatory blood pressure in patients with 
coronary artery disease. A systematic review suggests that 
paracetamol should be used with caution in patients with 
established coronary artery disease [9]. In fact, because of 
the widespread use of paracetamol (twice that of ibuprofen), 
this drug accounted for twice the number of CV events (203 
vs. 98), so maybe one should conclude that “All drugs are 
dangerous; and some may also be useful” [10].
Indication and protopathic biases and complex channeling 
effects exist in observational studies and only randomized 
trials can provide unbiased causal exposure and outcome 
measures. However, conventional randomized controlled 
trials are very expensive, time-consuming, and involve 
relatively small numbers of patients, and the potential to 
generalize their results is limited. Thus, large pharmacoepi-
demiology studies, such as the study by Doung et al. [2], 
are important.
The pattern of use of NSAIDs has changed in recent years 
due to the emerging evidence regarding associated CV risk, 
making it even more difficult to collect good real-world data 
on the risks of NSAIDs in the elderly and patients at higher 
CV risk in the future. The Duong et al. [2] study is a wel-
come addition to the literature.
Data from clinical trials, meta-analyses, and large phar-
macoepidemiology studies have shown that low, analgesic 
doses of ibuprofen have a low risk for acute coronary disease 
when used in low CV risk people. However, in high CV risk 
subjects the PRECISION trial suggests that celecoxib could 
be safer, at least from a kidney and gastrointestinal point of 
view. Indeed, PRECISION had ‘signals’ that even naproxen 
was worse than celecoxib for mortality, renal events, and 
gastrointestinal events.
The study by Doung et al. [2] is an example of how efforts 
to advance the use of real-world data to generate real-world 
evidence continue to move forward and shows that they are 
able to provide useful and relevant information about the 
safety of commonly used medicines.
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